Pfizer to Pay up to $525 Million for Lung-Focused Biotech

5:20am PDT - April 7th, 2022    johnson and johnson vaccine - Bloomberg

Pfizer Inc. agreed to buy respiratory antiviral developer ReViral Ltd. for as much as $525 million, the Covid-19 vaccine maker’s latest move in the once-overlooked field of infectious disease.